Microinjection of a p21ras antibody into PC12 cells inhibits neurite outgrowth induced by nerve growth factor and basic fibroblast growth factor.
The role of p21ras in signal transduction in PC12 cells was studied using an antibody that blocks its function. Native cells were microinjected with either a control solution or a solution containing the monoclonal antibody Y13-259. Treatment of the cells with growth factors appeared to enhance the ability of the cells to survive the microinjection procedure. Of the cells microinjected with the control solution 66-69% of those treated with either nerve growth factor (NGF) or basic fibroblast growth factor (bFGF) were still present 24 h post-injection, compared with only 57% for those not treated with growth factor after microinjection. This effect of the growth factors was inhibited by introduction of the Y13-259 antibody, suggesting that it occurs through a pathway that involves p21ras. Similarly, introduction of the Y13-259 antibody into cells also resulted in a statistically significant decrease in the percentage of neurite-bearing cells; 25-36% of the cells microinjected with the control solution had neurites, whereas 12-14% of the cells microinjected with the antibody solution had neurites. This decrease suggests that the induction of neurite outgrowth and the maintenance of established neurites by these growth factors is dependent on a functional p21ras pathway. As well as complementing the finding that p21ras is apparently involved in the mechanism of action of NGF in PC12 cells, these results further establish (1) that p21ras is also involved in the mechanism of action of bFGF, and (2) that the effect of NGF and bFGF on the number of labeled cells still present 24 h postinjection requires a functional p21ras protein.
Altin
J G
JG
Department of Biological Chemistry, California College of Medicine, Irvine.
Wetts
R
R
Bradshaw
R A
RA
D000310:Adrenal Gland Neoplasms / Q000473:pathology; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000494:pharmacology*; D001369:Axons / Q000276:immunology; D002452:Cell Count; D002455:Cell Division / Q000276:immunology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D008845:Microinjections; D009414:Nerve Growth Factors / Q000494:pharmacology*; D015689:Oncogene Protein p21(ras) / Q000235:genetics / Q000276:immunology*; D010673:Pheochromocytoma / Q000473:pathology; D051381:Rats; D015398:Signal Transduction / Q000235:genetics; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000911:Antibodies, Monoclonal; D009414:Nerve Growth Factors; D016222:Fibroblast Growth Factor 2; D015689:Oncogene Protein p21(ras)